Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (22)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Fuchs, P. C.
Right arrow Articles by Brown, S. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fuchs, P. C.
Right arrow Articles by Brown, S. D.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy (1999) 43, 703-706
© 1999 The British Society for Antimicrobial Chemotherapy

Brief report

In-vitro antimicrobial activity of a carbapenem, MK-0826 (L-749,345) and provisional interpretive criteria for disc tests

Peter C. Fuchs*, Arthur L. Barry and Steven D. Brown

The Clinical Microbiology Institute, 9725 SW Commerce Circle, Suite A-1, Wilsonville, OR 97070, USA

The in-vitro activity of MK-0826, a new oral carbapenem, was compared with that of imipenem by broth microdilution susceptibility tests against 545 bacterial isolates. MK-0826 had significantly greater activity against Enterobacteriaceae and poorer activity against Pseudomonas aeruginosa and many Gram-positive species. MK-0826 disc diffusion tests were also performed according to the NCCLS procedure and tentative interpretive criteria were determined for possible susceptible MIC breakpoints of <=4.0 and <=2.0 mg/L.

* Corresponding author. Tel: +1-503-682-3232; Fax: +1-503-682-2065


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J Antimicrob ChemotherHome page
A. Alhambra, J. A. Cuadros, J. Cacho, J. L. Gomez-Garces, and J. I. Alos
In vitro susceptibility of recent antibiotic-resistant urinary pathogens to ertapenem and 12 other antibiotics
J. Antimicrob. Chemother., June 1, 2004; 53(6): 1090 - 1094.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
E. J. C. Goldstein, D. M. Citron, C. V. Merriam, Y. A. Warren, K. L. Tyrrell, and H. Fernandez
Comparative In Vitro Activities of Ertapenem (MK-0826) against 469 Less Frequently Identified Anaerobes Isolated from Human Infections
Antimicrob. Agents Chemother., April 1, 2002; 46(4): 1136 - 1140.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
G. A. Pankuch, T. A. Davies, M. R. Jacobs, and P. C. Appelbaum
Antipneumococcal Activity of Ertapenem (MK-0826) Compared to Those of Other Agents
Antimicrob. Agents Chemother., January 1, 2002; 46(1): 42 - 46.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
D. B. Hoellman, L. M. Kelly, K. Credito, L. Anthony, L. M. Ednie, M. R. Jacobs, and P. C. Appelbaum
In Vitro Antianaerobic Activity of Ertapenem (MK-0826) Compared to Seven Other Compounds
Antimicrob. Agents Chemother., January 1, 2002; 46(1): 220 - 224.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
E. J. C. Goldstein, D. M. Citron, C. V. Merriam, Y. A. Warren, K. Tyrrell, and H. Fernandez
Comparative in vitro activity of ertapenem and 11 other antimicrobial agents against aerobic and anaerobic pathogens isolated from skin and soft tissue animal and human bite wound infections
J. Antimicrob. Chemother., November 1, 2001; 48(5): 641 - 651.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
C. Betriu, A. Sanchez, M. L. Palau, M. Gomez, and J. J. Picazo
In Vitro Activities of MK-0826 and 16 Other Antimicrobials against Bacteroides fragilis Group Strains
Antimicrob. Agents Chemother., August 1, 2001; 45(8): 2372 - 2374.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
D. M. Livermore, M. W. Carter, S. Bagel, B. Wiedemann, F. Baquero, E. Loza, H. P. Endtz, N. van den Braak, C. J. Fernandes, L. Fernandes, et al.
In Vitro Activities of Ertapenem (MK-0826) against Recent Clinical Bacteria Collected in Europe and Australia
Antimicrob. Agents Chemother., June 1, 2001; 45(6): 1860 - 1867.
[Abstract] [Full Text]

Home page
 Antimicrob. Agents Chemother.Home page
P. C. Fuchs, A. L. Barry, and S. D. Brown
In Vitro Activities of Ertapenem (MK-0826) against Clinical Bacterial Isolates from 11 North American Medical Centers
Antimicrob. Agents Chemother., June 1, 2001; 45(6): 1915 - 1918.
[Abstract] [Full Text]

Home page
 Antimicrob. Agents Chemother.Home page
E. J. C. Goldstein, D. M. Citron, C. Vreni Merriam, Y. Warren, and K. L. Tyrrell
Comparative In Vitro Activities of Ertapenem (MK-0826) against 1,001 Anaerobes Isolated from Human Intra-Abdominal Infections
Antimicrob. Agents Chemother., September 1, 2000; 44(9): 2389 - 2394.
[Abstract] [Full Text]

Home page
 Antimicrob. Agents Chemother.Home page
H. M. Wexler, D. Molitoris, and S. M. Finegold
In Vitro Activities of MK-826 (L-749,345) against 363 Strains of Anaerobic Bacteria
Antimicrob. Agents Chemother., August 1, 2000; 44(8): 2222 - 2224.
[Abstract] [Full Text]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.